364 related articles for article (PubMed ID: 17407364)
1. Emerging treatments and gene expression profiling in high-risk medulloblastoma.
Sardi I; Cavalieri D; Massimino M
Paediatr Drugs; 2007; 9(2):81-96. PubMed ID: 17407364
[TBL] [Abstract][Full Text] [Related]
2. Medulloblastoma: what is the role of molecular genetics?
Entz-Werle N; Carli ED; Ducassou S; Legrain M; Grill J; Dufour C
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1169-81. PubMed ID: 18588461
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma: from molecular pathology to therapy.
Rossi A; Caracciolo V; Russo G; Reiss K; Giordano A
Clin Cancer Res; 2008 Feb; 14(4):971-6. PubMed ID: 18281528
[TBL] [Abstract][Full Text] [Related]
4. A molecular fingerprint for medulloblastoma.
Lee Y; Miller HL; Jensen P; Hernan R; Connelly M; Wetmore C; Zindy F; Roussel MF; Curran T; Gilbertson RJ; McKinnon PJ
Cancer Res; 2003 Sep; 63(17):5428-37. PubMed ID: 14500378
[TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma: mouse models and novel targeted therapies based on the Sonic hedgehog pathway.
Piedimonte LR; Wailes IK; Weiner HL
Neurosurg Focus; 2005 Nov; 19(5):E8. PubMed ID: 16398472
[TBL] [Abstract][Full Text] [Related]
6. Rethinking medulloblastoma from a targeted therapeutics perspective.
Hashimoto Y; Penas-Prado M; Zhou S; Wei J; Khatua S; Hodges TR; Sanai N; Xiu J; Gatalica Z; Kim L; Kesari S; Rao G; Spetzler D; Heimberger A
J Neurooncol; 2018 Sep; 139(3):713-720. PubMed ID: 29869738
[TBL] [Abstract][Full Text] [Related]
7. Medulloblastoma molecular dissection: the way toward targeted therapy.
Remke M; Ramaswamy V; Taylor MD
Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients.
Chou PM; Reyes-Mugica M; Barquin N; Yasuda T; Tan X; Tomita T
Pediatr Neurosurg; 1995; 23(6):283-91; discussion 291-2. PubMed ID: 8743996
[TBL] [Abstract][Full Text] [Related]
9. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
Pizer BL; Clifford SC
Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
[TBL] [Abstract][Full Text] [Related]
10. Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile.
Sadighi Z; Vats T; Khatua S
J Child Neurol; 2012 Oct; 27(10):1302-7. PubMed ID: 22826514
[TBL] [Abstract][Full Text] [Related]
11. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
[TBL] [Abstract][Full Text] [Related]
12. Gene expression monitoring accurately predicts medulloblastoma positive and negative clinical outcomes.
Korenberg MJ
FEBS Lett; 2003 Jan; 533(1-3):110-4. PubMed ID: 12505168
[TBL] [Abstract][Full Text] [Related]
13. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.
Neben K; Korshunov A; Benner A; Wrobel G; Hahn M; Kokocinski F; Golanov A; Joos S; Lichter P
Cancer Res; 2004 May; 64(9):3103-11. PubMed ID: 15126347
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T; Shirsat N; Jalali R
Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
[TBL] [Abstract][Full Text] [Related]
15. Childhood medulloblastoma: current status of biology and treatment.
Klesse LJ; Bowers DC
CNS Drugs; 2010 Apr; 24(4):285-301. PubMed ID: 20297854
[TBL] [Abstract][Full Text] [Related]
16. Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment.
Liang Y; Diehn M; Bollen AW; Israel MA; Gupta N
J Neurooncol; 2008 Jan; 86(2):133-41. PubMed ID: 17653508
[TBL] [Abstract][Full Text] [Related]
17. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Mendrzyk F; Radlwimmer B; Joos S; Kokocinski F; Benner A; Stange DE; Neben K; Fiegler H; Carter NP; Reifenberger G; Korshunov A; Lichter P
J Clin Oncol; 2005 Dec; 23(34):8853-62. PubMed ID: 16314645
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of medulloblastoma: an overview with an emphasis on molecular biology.
de Haas TG; Kool M
Clin Neuropathol; 2007; 26(3):93-110. PubMed ID: 19157001
[TBL] [Abstract][Full Text] [Related]
19. [Medulloblastoma: The latest major advances].
Contenti J; Bost F; Mazure NM
Bull Cancer; 2023 Apr; 110(4):412-423. PubMed ID: 36822958
[TBL] [Abstract][Full Text] [Related]
20. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
